GlassScriptPhysician profile
Abhinav Vemula
NPI 1508109281
$4,017.88
in general payments reported to CMS, 2019-2025
26 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $854 · 2024: $1,193 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,684 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.76 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $926.52 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $705.04 | 2022-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $484.34 | 2022-2025 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $326.33 | 2023-2025 | Tremfya, Remicade, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $197.39 | 2022-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $183.17 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $158.25 | 2025 | Iqirvo |
| Ardelyx, INC. | $146.05 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $120.20 | 2023-2025 | Sucraid |
| Pfizer INC. | $110.73 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $108.54 | 2024-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $79.00 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $66.73 | 2025 | Voquezna |
| Celgene Corporation | $65.35 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $51.34 | 2023 | Dificid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $47.56 | 2023-2025 | Gimoti |
| Intercept Pharmaceuticals, INC. | $40.22 | 2022-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $35.65 | 2024 | Resmetirom |
| Fresenius Kabi USA, LLC | $33.01 | 2024-2025 | Idacio, Adalimumab-Aacf |
| Micro-Tech Endoscopy USA, INC. | $30.09 | 2025 | |
| Celltrion USA INC. | $26.50 | 2024 | Vegzelma |
| Ferring Pharmaceuticals INC. | $22.64 | 2023 | Clenpiq |
| Ironwood Pharmaceuticals, INC | $21.10 | 2023 | Linzess |
| Braintree Laboratories, INC. | $17.84 | 2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $14.29 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,984.14 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhinav Vemula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.